Trials / Completed
CompletedNCT00749866
Long Term Nebulised Gentamicin in Patients With Bronchiectasis
Can Long Term Nebulised Gentamicin Reduce The Bacterial Burden, Break the Vicious Cycle of Inflammation and Improve Quality of Life in Patients With Bronchiectasis
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- University of Edinburgh · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The hypothesis of this randomized placebo controlled trial is that targeted nebulized gentamicin to the airways will reduce bacterial burden and limit neutrophil airways inflammation. If given long term this will improve symptoms, pulmonary physiology, exercise capacity and health related quality of life with a reduction in exacerbation frequency and health care utilization.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gentamicin | Nebulised 80mg twice daily |
| DRUG | Saline | Nebulised 4mls 0.9% Saline twice daily |
Timeline
- Start date
- 2007-05-01
- Primary completion
- 2009-08-01
- Completion
- 2009-08-01
- First posted
- 2008-09-09
- Last updated
- 2010-08-10
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT00749866. Inclusion in this directory is not an endorsement.